Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.49 EUR
−145.80 M EUR
57.56 M EUR
97.96 M
About Fate Therapeutics, Inc.
Sector
Industry
CEO
Bahram Valamehr
Website
Headquarters
San Diego
Founded
2007
FIGI
BBG005CNC5Y2
Fate Therapeutics, Inc. engages in the development of programmed cellular immunotherapies for cancer and immune disorder. Its pipeline of products includes immuno-ocology candidates and immuno-regulation candidates. The company was founded by Philip Beachy, Sheng Ding, Rudolf Jaenisch, Randall T. Moon, Michael Rudnicki, David Scadden, Leonard Zon, Alexander Rives, Scott Wolchko, and John D. Mendlein on April 27, 2007 and is headquartered in San Diego, CA.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of F6T is 1.60 EUR — it has decreased by −0.50% in the past 24 hours. Watch FATE THERAPEUTICS INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on GETTEX exchange FATE THERAPEUTICS INC stocks are traded under the ticker F6T.
F6T stock has risen by 3.27% compared to the previous week, the month change is a −35.75% fall, over the last year FATE THERAPEUTICS INC has showed a −60.76% decrease.
We've gathered analysts' opinions on FATE THERAPEUTICS INC future price: according to them, F6T price has a max estimate of 9.44 EUR and a min estimate of 2.83 EUR. Watch F6T chart and read a more detailed FATE THERAPEUTICS INC stock forecast: see what analysts think of FATE THERAPEUTICS INC and suggest that you do with its stocks.
F6T stock is 2.82% volatile and has beta coefficient of 2.19. Track FATE THERAPEUTICS INC stock price on the chart and check out the list of the most volatile stocks — is FATE THERAPEUTICS INC there?
Today FATE THERAPEUTICS INC has the market capitalization of 184.35 M, it has decreased by −10.94% over the last week.
Yes, you can track FATE THERAPEUTICS INC financials in yearly and quarterly reports right on TradingView.
FATE THERAPEUTICS INC is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
F6T earnings for the last quarter are −0.36 EUR per share, whereas the estimation was −0.37 EUR resulting in a 3.95% surprise. The estimated earnings for the next quarter are −0.42 EUR per share. See more details about FATE THERAPEUTICS INC earnings.
FATE THERAPEUTICS INC revenue for the last quarter amounts to 2.76 M EUR, despite the estimated figure of 1.12 M EUR. In the next quarter, revenue is expected to reach 1.57 M EUR.
F6T net income for the last quarter is −42.82 M EUR, while the quarter before that showed −35.88 M EUR of net income which accounts for −19.36% change. Track more FATE THERAPEUTICS INC financial stats to get the full picture.
No, F6T doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Jan 9, 2025, the company has 181.00 employees. See our rating of the largest employees — is FATE THERAPEUTICS INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. FATE THERAPEUTICS INC EBITDA is −159.48 M EUR, and current EBITDA margin is −250.78%. See more stats in FATE THERAPEUTICS INC financial statements.
Like other stocks, F6T shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade FATE THERAPEUTICS INC stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So FATE THERAPEUTICS INC technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating FATE THERAPEUTICS INC stock shows the sell signal. See more of FATE THERAPEUTICS INC technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.